Marico's Q1 FY26 revenue rise of 23% resurfaces, India business gains 27%
Resurfacing an August-reported update: Marico posted Q1 FY26 consolidated net profit of Rs 513 crore, up 8.2% year on year, on revenue growth of 23.3% to Rs 3,259 crore. India revenue rose 27.2%, while international revenue grew 12.9%. The company also increased its stake in Plix maker Satiya Nutraceuticals to 60%.
What happened
Marico reported Q1 FY26 profit growth of 8.2% and revenue growth of 23.3%, led by a 27.2% rise in India sales. The FMCG company raised its stake in Plix maker
Key facts
- Q1 FY26 consolidated net profit rose 8.2% YoY to Rs 513 crore from Rs 474 crore
- Revenue from operations increased 23.31% to Rs 3,259 crore from Rs 2,643 crore
- Total income was Rs 3,315 crore, including Rs 56 crore other income
- Total expenses rose to Rs 2,659 crore from Rs 2,075 crore
- India revenue rose 27.17% to Rs 2,495 crore from Rs 1,962 crore
- International revenue grew 12.91% to Rs 764 crore from Rs 681 crore
- India PBT was Rs 469 crore; international PBT was Rs 213 crore
- Marico increased its Satiya Nutraceuticals stake to 60% on a fully diluted basis
Why this matters
Increasing ownership in Plix maker Satiya Nutraceuticals to 60% strengthens Marico’s position in the high-growth health and nutrition segment while extending its portfolio beyond core FMCG categories.
What to watch
- India volume growth versus the 27.2% revenue growth rate, separating pricing from underlying consumption.
- Gross-margin and EBITDA-margin trajectory, especially commentary on copra, edible oil, packaging and freight costs.
- Plix revenue growth, profitability, channel expansion and evidence that consolidation contributes meaningfully to earnings.
- International constant-currency growth and currency translation effects across Bangladesh, MENA, South Africa and Southeast Asia.
- Advertising spend intensity, market-share trends and management guidance for FY26 revenue and margin.
- Use the Plix majority stake to widen omnichannel distribution, cross-sell nutrition products and consolidate wellness-brand supply chains.
- Prioritise calibrated price increases, pack-size changes and hedging/procurement actions to protect gross margin if commodity costs rise.
- Increase advertising and retail execution behind faster-growing India portfolios while defending market share in Parachute, Saffola and value-led categories.
- Seek further portfolio adjacencies in premium personal care, foods and health-led consumption rather than relying solely on mature coconut-oil demand.